(Q37850804)

24 August 2017

1 reference

title

Lubiprostone for the treatment of opioid-induced bowel dysfunction (English)

1 reference

24 August 2017

0 references

2

Michael Camilleri

1 reference

24 August 2017

Banny S Wong

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

9 March 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

983-990

1 reference

Trends in long-term opioid therapy for chronic non-cancer pain

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Gastrointestinal side effects in chronic opioid users: results from a population-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Utility assessments of opioid treatment for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Opioid-induced bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Incidence, prevalence, and management of opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

The relationship between opioid use and laxative use in terminally ill cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Opioids in chronic non-cancer pain: systematic review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Treatment of opioid-induced gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Electrolyte Disorders Following Oral Sodium Phosphate Administration for Bowel Cleansing in Elderly Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Adverse effects of laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Development of peripheral opioid antagonists' new insights into opioid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

A long-term survey of morphine in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Reducing the gastrointestinal risks of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566559

10.1517/14656566.2011.566559

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference